067 - Diabetes: does it cost a heart and a leg?

Published: Sept. 26, 2017, 10 a.m.

b'

In this episode, we discuss new evidence for cardiovascular outcomes in diabetics based on the LEADER trial (liraglutide) and CANVAS trials (canagliflozin). We also discuss the new FDA warning for canagliflozin regarding amputation risk.

'